A Dose Ranging Study to Evaluate the Safety and Efficacy of GSK2586184 in Patients With Chronic Plaque Psoriasis

A Multi-centre, Randomised, Double-blind, Placebo-controlled, Dose Ranging Study to Evaluate the Safety and Efficacy of GSK2586184 in Patients With Chronic Plaque Psoriasis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01782664

Enrollment

Registered

2013-02-04

Start date

2013-03-01

Completion date

2014-03-24

Last updated

2017-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Keywords

PASI, DLQI, GSK2586184, plaque-type psoriasis, PGA, inflammatory gene transcription, JAK-1 inhibitor, serum neopterin, skin biopsy, ACR response criteria, VAS itch score

Brief summary

A multi-centre, randomised, dose ranging study to evaluate the safety and clinical efficacy of GSK2586184 in patients with chronic plaque psoriasis. There will be 2 study cohorts (Cohorts A and B). Cohort A is the main study cohort, and this part of the study will be randomised, double-blind and placebo-controlled. Fifty-six subjects will be randomised in Cohort A: 14 subjects in each treatment group: 100 mg, 200 mg or 400 mg GSK2586184, or placebo. Cohort B is an exploratory, open-label investigation of the effect of 400 mg GSK2586184 on inflammatory gene expression in the skin and whole blood, and GSK2586184 concentrations in the skin. A maximum of 8 subjects will be included, and all subjects will take 400 mg GSK2586184. In both Cohorts A and B, study medication will be administered orally (as tablets), twice daily, for up to 12 weeks. Each subject will have 7 out-patient visits: Screening; Baseline & Start of treatment; Week 2; Week 4; Week 8; Week 12; and Follow-up (Week 16)

Interventions

DRUG100 mg GSK2586184

100 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.

DRUG200 mg GSK2586184

200 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.

DRUG400 mg GSK2586184

400 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.

DRUGPlacebo

Placebo tablets to be taken twice daily with food for up to 84 days.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Otherwise healthy subjects with a diagnosis of moderate to severe plaque psoriasis defined by the following criteria: * Diagnosed for at least 12 months before the first dose of study medication * Psoriasis plaques cover \>=10% of body surface area. * PASI score of \>=12, and PGA score of\>=3, and suitable for systemic or light therapy. * Male or female, between 18 and 75 years of age inclusive. * Female subjects of childbearing potential must agree to avoid pregnancy and male subjects must agree to avoid female partners becoming pregnant. * Subjects must agree to use ultra violet (UV) light protection. * Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion criteria

* Unable to refrain from the use of the following prescription and non-prescription drugs from the following periods before the first dose of study medication until completion of the follow-up visit: * 12 weeks: alefacept, ustekinumab, adalimumab, etanercept, infliximab, or certolizumab pegol * 4 weeks or 5 half-lives, whichever is longer: * systemic medications for other medical conditions that are known to affect psoriasis, including but not limited to oral corticosteroids, cyclosporine, methotrexate, lithium, and beta-adrenergic blockers * 7 days or 5 half-lives, whichever is longer: * statins and other OATP and BCRP sensitive substrates (e.g. rapaglinide) * any agent known to be a substrate of MATE1 and MATE2-K, which undergoes significant renal secretion (e.g. cimetidine) * 3 weeks or 5 half-lives, whichever is longer: * any agent known to be a strong CYP3A4 inhibitor or inducer * 2 weeks: topical therapies that are known to affect psoriasis, including but not limited to corticosteroids, retinoids, vitamin D derivatives, tar and anthralin * Other medications (including vitamins, herbal and dietary supplements) will be considered on a case-by-case basis, and will be allowed if in the opinion of the investigator the medication will not interfere with the study procedures or compromise subject safety. * Phototherapy within 4 weeks before the first dose of study medication. * A live vaccination within 4 weeks before the first dose of study medication, or a live vaccination planned during the course of the study (until completion of the follow-up visit). * A major organ transplant (e.g. heart, lung, kidney, liver) or haematopoietic stem cell/marrow transplant. * Significant unstable or uncontrolled acute or chronic disease unrelated to psoriasis (i.e. cardiovascular including uncontrolled hypertension, hypercholesterolemia, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, malignancy or infectious diseases) which, in the opinion of the investigator, could confound the results of the study or put the subject at undue risk. * A planned surgical procedure that, in the opinion of the investigator, makes the subject unsuitable for the study. * A history of malignant neoplasm within the last 5 years, except for adequately treated cancers of the skin (basal or squamous cell) or carcinoma in situ of the uterine cervix. * Acute or chronic infections, as follows: * Known previous or active infection with Mycobacterium Tuberculosis * Currently on any suppressive therapy for a chronic infection (such as pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster and atypical mycobacteria). * Hospitalisation for treatment of infection within 60 days before first dose. * Use of parenteral (IV or intramuscular) antibiotics (antibacterials, antivirals, antifungals, or antiparasitic agents) within 60 days before first dose. * Unable to refrain from the consumption of grapefruit or grapefruit juice from 3 weeks before the first dose of study medication until 2 weeks after the last dose of study medication. * History of sensitivity to any components of the study medications, or a history of drug or other allergy that, in the opinion of the investigator, contraindicates their participation. * Serologic evidence of Hepatitis B (HB) infection based on the results of testing for HBsAg, anti-HBc antibody as follows: subjects positive for HBsAg are excluded; and subjects positive for anti-HBc antibody (regardless of anti-HBs antibody status) are excluded. * Positive test for Hepatitis C antibody confirmed sample with a Hepatitis C RIBA immunoblot assay or equivalent. Subjects who are positive for Hepatitis C antibody, but negative when the Hepatitis C RIBA immunoblot assay or equivalent test is performed will be eligible to participate. Subjects who are positive for Hepatitis C antibody and have a positive or indeterminate result when the Hepatitis C RIBA immunoblot assay or equivalent test is performed will not be eligible to participate. * A positive test for HIV antibody. * Pregnant females as determined by a positive serum hCG test at screening, or a positive urine hCG test pre-dose on Day 1. * Lactating females. * Haemoglobin \<11 g/dL, haematocrit \<30%, WBC count (absolute) \<3 × 10\^9/L, neutrophils \<1.5 × 10\^9/L, platelets \<100 × 10\^9/L, lymphocytes \<1 x 10\^9/L. * Current or history of renal disease, or estimated creatinine clearance \<60 mL/min/1.73m\^2 or serum creatinine \>1.5 ULN. * Single QTc \> 450 msec; or QTc \> 480 msec in subjects with Bundle Branch Block. * Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). * ALT \> 2xULN; alkaline phosphatase and bilirubin ≥ 1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%). * History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of \>21 units for males or \>14 units for females. One unit is equivalent to 8 g of alcohol: a half-pint (\ 240 ml) of beer, 1 glass (125 ml) of wine or 1 (25 ml) measure of spirits. * The subject has participated in a clinical trial and has received an investigational product within 3 months before the first dose of study medication, or plans to take part in another clinical trial at the same time as participating in this clinical trial.

Design outcomes

Primary

Measure	Time frame	Description
Percentage of Participants Who Had Achieved >=75% Improvement From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 12 (PASI 75)	Baseline and Week 12	PASI score was determined by evaluation of body surface area (BSA) covered by plaque psoriasis in 4 areas (head/neck, arms, trunk and legs with area score of 0.1, 0.2, 0.3 and 0.4 respectively). This test included combination of both degree of involvement (assessed as per the % of affected body area using a 7-point scale such that 0=0% involvement, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%) and severity (evaluated individually using a 5-point scale that ranged as 0=No evidence of sign, 1=slight evidence, 2=moderate evidence, 3=marked evidence and 4=very marked, most severe evidence of sign) of erythema, induration and desquamation in each of the same 4 areas. PASI score ranges from 0(no psoriasis) to 72(worse psoriasis). Final PASI=(sum of severity score for each area)x(% body affected score x area score). Baseline=Day 1. Percentage of participants who achieved \>= 75% improvement from Baseline was reported with last observation carried forward (LOCF) analysis.

Secondary

Measure	Time frame	Description
Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	From BL (Day 1) until the Follow-up visit (Day 112)	Hematology parameters included: basophils, eosinophils, erythrocyte mean corpuscular hemoglobin (EMCHb) EMCHb concentration (EMCHbC), erythrocyte mean corpuscular volume (EMCV), erythrocyte sedimentation rate (ESR), erythrocytes, hematocrit (fraction 1), hemoglobin, leukocytes, lymphocytes, monocytes, neutrophils, segmented neutrophils, platelets, reticulocytes. BL values were obtained at Day 1. The number of participants with the indicated hematology parameters data outside of the reference range (with high and low) any time post-BL are presented. Anytime post-BL assessments included any scheduled and unscheduled post-BL assessment.
Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study	From Baseline (Day 1) until the Follow-up visit (Day 112)	Safety and tolerability were assessed by measuring the clinical chemistry parameters such as creatinine and cystatin C. BL values were obtained at Day 1. The number of participants with the indicated hematology parameter data outside of the reference range (\> high or \< low) at any time post-BL, including unscheduled or scheduled assessments, are presented.
Number of Participants With the Systolic (S) and Diastolic (D) Blood Pressure (BP) Falling Outside the Clinical Concern Range at Any Time Post-baseline During the Study	From Baseline (Day 1) until the follow-up visit (Day 112)	Vital sign monitoring included systolic and diastolic BP measurements. BP measurements were taken in the supine position after 5 minutes of rest. The number of participants with the SBP or DBP outside the clinical concern range at any time post-BL are presented. SBP low was measured as less than 85 millimeters of mercury (mmHg)and high was measured as greater than 160 mmHg. DBP low was measured as less than 45 mmHg and high was measured as greater than 100 mmHg. The BL values were those values obtained at Day 1. Anytime post-BL assessments included any scheduled and unscheduled post-BL assessment.
Number of Participants With the Heart Rate Falling Outside the Clinical Concern Range at Any Time Post-Baseline (BL) During the Study	From Baseline (Day 1) until the Follow-up visit (Day 112)	Vital sign monitoring included heart rate (HR) measurements. HR measurements were taken in supine position after 5 minutes of rest. The number of participants with HR outside the clinical concern range at any time post-BL are presented. HR low was any HR less than 40 beats per minute (bpm) and high was any HR greater than 110 bpm. The BL values were those values obtained at Day 1. Anytime post-BL assessments included any scheduled and unscheduled post-BL assessment.
Change From Baseline in Body Temperature	From Baseline (Day 1) until Week 16	Vital sign monitoring included body temperature measurements. Body temperature measurements were taken in the supine position after 5 minutes of rest. Baseline is defined as the last result on or before the day of first dose. Change from Baseline was determined by subtracting the indicated time point value minus the Baseline value.
Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings	From Baseline (Day 1) until the Follow-up visit (Day 112)	ECG measurements were obtained using single 12-lead ECGs with the participant in a supine position after resting in this position for at least 10 minutes. The Baseline values were those values obtained Pre-dose on Day 1. The change from Baseline was the difference between post-Baseline and Baseline. The QT intervals (milliseconds \[msec\]) corrected for heart rate using Bazett's formula (QTcB) and Fridericia's formula (QTcF) are reported.
Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12	From Baseline (Day 1) until Week 12	Psoriatic lesions were assessed using the PASI. PASI score was determined by evaluation of BSA covered by plaque psoriasis in 4 areas (head/neck, arms, trunk and legs with area score of 0.1, 0.2, 0.3 and 0.4 respectively). This test included combination of both degree of involvement (assessed as per the % of affected body area using a 7-point scale such that 0=0% involvement, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%) and severity (evaluated individually using a 5-point scale that ranged as 0=No evidence of sign, 1=slight evidence, 2=moderate evidence, 3=marked evidence and 4=very marked, most severe evidence of sign) of erythema, induration and desquamation in each of the same 4 areas. PASI score ranges from 0(no psoriasis) to 72(worse psoriasis). Final PASI=(sum of severity score for each area)x(% body affected score x area score). Baseline=Day 1. The change from Baseline was the difference between post-Baseline and Baseline.
PASI Score at Week 2, 4, 8 and 12	Week 2, 4, 8 and 12	Psoriatic lesions were assessed using the PASI. PASI score was determined by evaluation of BSA covered by plaque psoriasis in 4 areas (head/neck, arms, trunk and legs with area score of 0.1, 0.2, 0.3 and 0.4 respectively). This test included combination of both degree of involvement (assessed as per the % of affected body area using a 7-point scale such that 0=0% involvement, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%) and severity (evaluated individually using a 5-point scale that ranged as 0=No evidence of sign, 1=slight evidence, 2=moderate evidence, 3=marked evidence and 4=very marked, most severe evidence of sign) of erythema, induration and desquamation in each of the same 4 areas. PASI score ranges from 0(no psoriasis) to 72(worse psoriasis). Final PASI=(sum of severity score for each area)x(% body affected score x area score). Baseline=Day 1.
Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	From Baseline (Day 1) until Week 12	Psoriatic lesions were assessed using the PASI. PASI score was determined by evaluation of BSA covered by plaque psoriasis in 4 areas (head/neck, arms, trunk and legs with area score of 0.1, 0.2, 0.3 and 0.4 respectively). This test included combination of both degree of involvement (assessed as per the % of affected body area using a 7-point scale such that 0=0% involvement, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%) and severity (evaluated individually using a 5-point scale that ranged as 0=No evidence of sign, 1=slight evidence, 2=moderate evidence, 3=marked evidence and 4=very marked, most severe evidence of sign) of erythema, induration and desquamation in each of the same 4 areas. PASI score ranges from 0(no psoriasis) to 72(worse psoriasis). Final PASI=(sum of severity score for each area)x(% body affected score x area score). Baseline was Day 1.
Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12	Weeks 2, 4, 8 and 12	The severity of psoriatic lesions over the whole body were assessed by the investigator using the PGA scoring system. A 0 to 6 point rating scale was used, as follows: 0 = Clear (no signs of psoriasis), 1 = Almost clear (slight elevation, scale and/or erythema), 2 = Mild (mild plaque elevation, scale and/or erythema), 3 = Mild to moderate (mild plaque elevation with moderate erythema and/or scale), 4 = Moderate (moderate plaque elevation, scale and/or erythema), 5 = Moderate to severe (marked plaque elevation, scale and/or erythema), 6 = Severe (very marked plaque elevation, scale and/or erythema). Higher scores indicated worse psoriasis. The Baseline value was the value obtained on Day 1. The scores were reported with the last observation carried forward (LOCF) analysis.
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)	From Baseline (Day 1) until the Follow-up visit (Day 112)	An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, is a congenital anomaly or birth defect. Any SAEs assessed as related to study participation (e.g. study treatment, protocol-mandated procedures, invasive tests, or change in existing therapy) or related to a GSK product was recorded from the time a participant consents to participate in the study up to and including any follow-up contact.
Time to PASI 75	From Baseline (Day 1) until Week 12	PASI 75 was \>= 75% improvement from Baseline in PASI score. Psoriatic lesions were assessed by the investigator using a PASI score. PASI score was determined by evaluation of BSA covered by plaque psoriasis in 4 areas (head/neck, arms, trunk and legs with area score of 0.1, 0.2, 0.3 and 0.4 respectively). This test included combination of both degree of involvement (assessed as per the % of affected body area using a 7-point scale such that 0=0% involvement, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%) and severity (evaluated individually using a 5-point scale that ranged as 0=No evidence of sign, 1=slight evidence, 2=moderate evidence, 3=marked evidence and 4=very marked, most severe evidence of sign) of erythema, induration and desquamation in each of the same 4 areas. PASI score ranges from 0(no psoriasis) to 72(worse psoriasis). Final PASI=(sum of severity score for each area)x(% body affected score x area score). Baseline was Day 1.
Time to PGA Score of 'Clear' (0) or 'Almost Clear' (1)	From Baseline (Day 1) until Week 12	The severity of psoriatic lesions over the whole body were assessed by the investigator using the PGA scoring system. A 0 to 6 point rating scale was used, as follows: 0 = Clear (no signs of psoriasis), 1 = Almost clear (slight elevation, scale and/or erythema), 2 = Mild (mild plaque elevation, scale and/or erythema), 3 = Mild to moderate (mild plaque elevation with moderate erythema and/or scale)4 = Moderate (moderate plaque elevation, scale and/or erythema), 5 = Moderate to severe (marked plaque elevation, scale and/or erythema), 6 = Severe (very marked plaque elevation, scale and/or erythema). The Baseline value was the value obtained on Day 1. The scores were reported with the last observation carried forward (LOCF) analysis.
Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12	From Baseline (Day 1) until Week 12	The visual analogue scale (VAS) was used to assess itch. The participants rated the intensity of itch over the past week by marking a line on a 100 millimeter(mm) (0 to 100 mm) long scale. A line placed on the extreme left, that is 0 mm indicated no noticeable itching sensation and extreme right that is 100 mm indicated maximum itching sensation. This scale has no subscales. The participant perception of their symptoms was measured using the VAS itch score. The Baseline value was the value obtained on Day 1. The change from Baseline was the difference between post-Baseline and Baseline.
Itch VAS Scores at Week 2, 4, 8 and 12	Week 2, 4, 8 and 12	The visual analogue scale (VAS) was used to assess itch. The participants rated the intensity of itch over the past week by marking a line on a 100 mm (0 to 100 mm) long scale. A line placed on the extreme left, that is 0 mm indicated no noticeable itching sensation and extreme right that is 100 mm indicated maximum itching sensation. This scale has no subscales. The participant perception of their symptoms was measured using the VAS itch score. Itch VAS scores at Week 2, 4, 8 and 12 are reported.
Change From Baseline of Dermatology Life Quality Index (DLQI) Score at Week 12	Baseline and Week 12	The DLQI was used to assess a participant's health-related quality of life. Participants completed the questionnaire to evaluate how their psoriasis affected their life over the week before the assessment took place. Each of the 10 questions was scored out of 0-3 as; 0 = Not at all, 1 = A little, 2 = A lot and 3 = Very much. The total score for the DLQI was calculated by adding up all the individual scores for each question resulting in a minimum of 0 and a maximum of 30. Higher score indicated worsening of participant's quality of life. The Baseline value was the value obtained on Day 1. The change from Baseline was the difference between post-Baseline and Baseline.
Population Pharmacokinetic (PK) Derived Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Time of the Last Measureable Concentration (AUC(0-tau) of GSK2586184	Baseline (pre-dose), Day 14 (2 to 3 hour and 3 to 4 hour post-dose), Day 28 (4 to 6 hour and 6 to 8 hour post-dose), Day 56 (at anytime during clinical visit), Day 84 (1 sample to be taken at anytime during clinical visit)	Blood samples were taken to measure plasma concentrations of GSK2586184. A two-compartment model with a three-compartment transit model was used to derive PK parameters.
Clearance of GSK2586184	Baseline (pre-dose), Day 14 (2 to 3 hour and 3 to 4 hour post-dose), Day 28 (4 to 6 hour and 6 to 8 hour post-dose), Day 56 (at anytime during clinical visit), Day 84 (1 sample to be taken at anytime during clinical visit)	Blood samples were taken to measure plasma concentrations of GSK2586184. A two-compartment model with a three-compartment transit model was used to derive PK parameters.
Steady State Volume of Distribution (Vss) of GSK2586184	Baseline (pre-dose), Day 14 (2 to 3 hour and 3 to 4 hour post-dose), Day 28 (4 to 6 hour and 6 to 8 hour post-dose), Day 56 (at anytime during clinical visit), Day 84 (1 sample to be taken at anytime during clinical visit)	Blood samples were taken to measure plasma concentrations of GSK2586184. A two-compartment model with a three-compartment transit model was used to derive PK parameters.
Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12	Baseline (pre-dose) and Weeks 2, 4, 8 and 12	Serum Neopterin is a marker of psoriatic disease activity. Blood samples were collected for estimation of serum neoprotein concentration. Baseline was Day 1. The change from Baseline was the difference between post-Baseline and Baseline.
Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Weeks 2, 4, 8 and 12	The severity of psoriatic lesions over the whole body were assessed by the investigator using the PGA scoring system. A 0 to 6 point rating scale was used, as follows: 0 = Clear (no signs of psoriasis), 1 = Almost clear (slight elevation, scale and/or erythema), 2 = Mild (mild plaque elevation, scale and/or erythema), 3 = Mild to moderate (mild plaque elevation with moderate erythema and/or scale), 4 = Moderate (moderate plaque elevation, scale and/or erythema), 5 = Moderate to severe (marked plaque elevation, scale and/or erythema), 6 = Severe (very marked plaque elevation, scale and/or erythema). Higher scores indicated worse psoriasis. The Baseline value was the value obtained on Day 1. The scores were reported with the last observation carried forward (LOCF) analysis.

Countries

Germany, United Kingdom

Participant flow

Recruitment details

A total of 68 participants with chronic plaque psoriasis were enrolled. The study was conducted at 13 centers in 2 countries: 10 in Germany and 3 in United Kingdom from 12 March 2013 to 24 March 2014.

Pre-assignment details

A total of 68 participants were enrolled for this study. Of these, 1 participant was not dosed any study medication because the participant was taking prohibited concomitant medications.

Participants by arm

Arm	Count
Placebo Participants received blinded matching placebo orally as tablets, with food, twice daily (BID), for up to 12 weeks.	14
GSK2586184 100 mg Participants received blinded 100 milligrams (mg) GSK2586184 orally as tablets, with food, BID, for up to 12 weeks.	15
GSK2586184 200 mg Participants received blinded 200 mg GSK2586184 orally as tablets, with food, BID, for up to 12 weeks.	16
GSK2586184 400 mg Participants received blinded 400 mg GSK2586184 orally as tablets, with food, BID, for up to 12 weeks.	14
GSK2586184 400 mg OL Participants received Open-Label 400 mg GSK2586184 orally as tablets, with food, BID, for up to 12 weeks.	6
GSK2586184 200 mg OL Participants incorrectly received Open-Label 200 mg (rather than 400 mg) GSK2586184 orally as tablets, with food, BID, for up to 12 weeks.	2
Total	67

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003
Overall Study	Adverse Event	2	2	2	2
Overall Study	Lack of Efficacy	2	0	2	2
Overall Study	Protocol Violation	0	1	0	1
Overall Study	Withdrawal by Subject	2	2	0	0

Baseline characteristics

Characteristic	Placebo	GSK2586184 100 mg	GSK2586184 200 mg	GSK2586184 400 mg	GSK2586184 400 mg OL	GSK2586184 200 mg OL	Total
Age, Continuous	49.0 Years STANDARD_DEVIATION 13.79	43.9 Years STANDARD_DEVIATION 14.1	49.0 Years STANDARD_DEVIATION 13.24	41.5 Years STANDARD_DEVIATION 12.08	50.7 Years STANDARD_DEVIATION 11.96	53.5 Years STANDARD_DEVIATION 2.12	46.6 Years STANDARD_DEVIATION 13.11
Race/Ethnicity, Customized African American/African Heritage	0 Participants	0 Participants	2 Participants	0 Participants	0 Participants	0 Participants	2 Participants
Race/Ethnicity, Customized Asian - South East Asian Heritage	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Race/Ethnicity, Customized White - White/Caucasian/European Heritage	14 Participants	14 Participants	14 Participants	14 Participants	6 Participants	2 Participants	64 Participants
Sex: Female, Male Female	5 Participants	6 Participants	6 Participants	8 Participants	3 Participants	2 Participants	30 Participants
Sex: Female, Male Male	9 Participants	9 Participants	10 Participants	6 Participants	3 Participants	0 Participants	37 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk
deaths Total, all-cause mortality	0 / 14	0 / 15	0 / 16	0 / 14	0 / 6	0 / 2
other Total, other adverse events	13 / 14	10 / 15	14 / 16	10 / 14	6 / 6	1 / 2
serious Total, serious adverse events	0 / 14	2 / 15	0 / 16	1 / 14	1 / 6	0 / 2

Outcome results

Primary

Percentage of Participants Who Had Achieved >=75% Improvement From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 12 (PASI 75)

PASI score was determined by evaluation of BSA covered by plaque psoriasis in 4 areas (head/neck, arms, trunk and legs with area score of 0.1, 0.2, 0.3 and 0.4 respectively). This test included combination of both degree of involvement (assessed as per the % of affected body area using a 7-point scale such that 0=0% involvement, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%) and severity (evaluated individually using a 5-point scale that ranged as 0=No evidence of sign, 1=slight evidence, 2=moderate evidence, 3=marked evidence and 4=very marked, most severe evidence of sign) of erythema, induration and desquamation in each of the same 4 areas. PASI score ranges from 0(no psoriasis) to 72(worse psoriasis). Final PASI=(sum of severity score for each area)x(% body affected score x area score). Baseline=Day 1. Percentage of participants who achieved \>= 75% improvement from Baseline was reported with LOCF analysis.

Time frame: Baseline and Week 12

Population: Per-Protocol Population: Participants in the ITT analysis set who had no major protocol deviations.

Arm	Measure	Value (NUMBER)
Placebo	Percentage of Participants Who Had Achieved >=75% Improvement From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 12 (PASI 75)	0 Percentage of participants
GSK2586184 100 mg	Percentage of Participants Who Had Achieved >=75% Improvement From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 12 (PASI 75)	14 Percentage of participants
GSK2586184 200 mg	Percentage of Participants Who Had Achieved >=75% Improvement From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 12 (PASI 75)	36 Percentage of participants
GSK2586184 400 mg	Percentage of Participants Who Had Achieved >=75% Improvement From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 12 (PASI 75)	62 Percentage of participants
GSK2586184 400 mg OL	Percentage of Participants Who Had Achieved >=75% Improvement From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 12 (PASI 75)	75 Percentage of participants

Primary

Percentage of Participants Who Had Achieved >=75% Improvement From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 12 (PASI 75)

PASI score was determined by evaluation of body surface area (BSA) covered by plaque psoriasis in 4 areas (head/neck, arms, trunk and legs with area score of 0.1, 0.2, 0.3 and 0.4 respectively). This test included combination of both degree of involvement (assessed as per the % of affected body area using a 7-point scale such that 0=0% involvement, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%) and severity (evaluated individually using a 5-point scale that ranged as 0=No evidence of sign, 1=slight evidence, 2=moderate evidence, 3=marked evidence and 4=very marked, most severe evidence of sign) of erythema, induration and desquamation in each of the same 4 areas. PASI score ranges from 0(no psoriasis) to 72(worse psoriasis). Final PASI=(sum of severity score for each area)x(% body affected score x area score). Baseline=Day 1. Percentage of participants who achieved \>= 75% improvement from Baseline was reported with last observation carried forward (LOCF) analysis.

Time frame: Baseline and Week 12

Population: Intent-to-Treat (ITT) Population: participants who received at least one dose of study medication.

Arm	Measure	Value (NUMBER)
Placebo	Percentage of Participants Who Had Achieved >=75% Improvement From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 12 (PASI 75)	0 Percentage of participants
GSK2586184 100 mg	Percentage of Participants Who Had Achieved >=75% Improvement From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 12 (PASI 75)	13 Percentage of participants
GSK2586184 200 mg	Percentage of Participants Who Had Achieved >=75% Improvement From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 12 (PASI 75)	25 Percentage of participants
GSK2586184 400 mg	Percentage of Participants Who Had Achieved >=75% Improvement From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 12 (PASI 75)	57 Percentage of participants
GSK2586184 400 mg OL	Percentage of Participants Who Had Achieved >=75% Improvement From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 12 (PASI 75)	50 Percentage of participants
GSK2586184 200 mg OL	Percentage of Participants Who Had Achieved >=75% Improvement From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 12 (PASI 75)	50 Percentage of participants

Secondary

Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12

Psoriatic lesions were assessed using the PASI. PASI score was determined by evaluation of BSA covered by plaque psoriasis in 4 areas (head/neck, arms, trunk and legs with area score of 0.1, 0.2, 0.3 and 0.4 respectively). This test included combination of both degree of involvement (assessed as per the % of affected body area using a 7-point scale such that 0=0% involvement, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%) and severity (evaluated individually using a 5-point scale that ranged as 0=No evidence of sign, 1=slight evidence, 2=moderate evidence, 3=marked evidence and 4=very marked, most severe evidence of sign) of erythema, induration and desquamation in each of the same 4 areas. PASI score ranges from 0(no psoriasis) to 72(worse psoriasis). Final PASI=(sum of severity score for each area)x(% body affected score x area score). Baseline=Day 1. The change from Baseline was the difference between post-Baseline and Baseline.

Time frame: From Baseline (Day 1) until Week 12

Population: ITT Population. Only those participants available at the specified time points were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12	Week 2	-0.05 Scores on a Scale	Standard Deviation 1.716
Placebo	Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12	Week 4	-0.73 Scores on a Scale	Standard Deviation 3.335
Placebo	Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12	Week 8	-1.41 Scores on a Scale	Standard Deviation 2.122
Placebo	Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12	Week 12	-3.13 Scores on a Scale	Standard Deviation 2.694
GSK2586184 100 mg	Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12	Week 8	-6.54 Scores on a Scale	Standard Deviation 6.915
GSK2586184 100 mg	Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12	Week 4	-4.50 Scores on a Scale	Standard Deviation 4.344
GSK2586184 100 mg	Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12	Week 2	-2.39 Scores on a Scale	Standard Deviation 3.12
GSK2586184 100 mg	Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12	Week 12	-9.76 Scores on a Scale	Standard Deviation 6.341
GSK2586184 200 mg	Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12	Week 12	-9.21 Scores on a Scale	Standard Deviation 12.446
GSK2586184 200 mg	Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12	Week 8	-8.45 Scores on a Scale	Standard Deviation 11.396
GSK2586184 200 mg	Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12	Week 4	-7.03 Scores on a Scale	Standard Deviation 7.594
GSK2586184 200 mg	Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12	Week 2	-0.51 Scores on a Scale	Standard Deviation 7.693
GSK2586184 400 mg	Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12	Week 2	-3.94 Scores on a Scale	Standard Deviation 4.766
GSK2586184 400 mg	Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12	Week 12	-13.55 Scores on a Scale	Standard Deviation 6.393
GSK2586184 400 mg	Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12	Week 4	-8.04 Scores on a Scale	Standard Deviation 7.739
GSK2586184 400 mg	Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12	Week 8	-10.32 Scores on a Scale	Standard Deviation 8.293
GSK2586184 400 mg OL	Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12	Week 8	-7.85 Scores on a Scale	Standard Deviation 5.39
GSK2586184 400 mg OL	Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12	Week 12	-9.37 Scores on a Scale	Standard Deviation 7.181
GSK2586184 400 mg OL	Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12	Week 4	-9.10 Scores on a Scale	Standard Deviation 3.854
GSK2586184 400 mg OL	Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12	Week 2	-5.25 Scores on a Scale	Standard Deviation 4.192
GSK2586184 200 mg OL	Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12	Week 4	-8.20 Scores on a Scale	Standard Deviation 0.99
GSK2586184 200 mg OL	Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12	Week 8	-11.50 Scores on a Scale	Standard Deviation 0.424
GSK2586184 200 mg OL	Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12	Week 12	-12.45 Scores on a Scale	Standard Deviation 1.061
GSK2586184 200 mg OL	Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12	Week 2	-3.75 Scores on a Scale	Standard Deviation 2.192

Secondary

Change From Baseline in Body Temperature

Vital sign monitoring included body temperature measurements. Body temperature measurements were taken in the supine position after 5 minutes of rest. Baseline is defined as the last result on or before the day of first dose. Change from Baseline was determined by subtracting the indicated time point value minus the Baseline value.

Time frame: From Baseline (Day 1) until Week 16

Population: ITT Population. Only those participants available at the specified time points were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Change From Baseline in Body Temperature	Week 16	0.3 Celsius	Standard Deviation 0.45
Placebo	Change From Baseline in Body Temperature	Week 2	-0.2 Celsius	Standard Deviation 0.54
Placebo	Change From Baseline in Body Temperature	Week 8	0.1 Celsius	Standard Deviation 0.44
Placebo	Change From Baseline in Body Temperature	Week 4	-0.1 Celsius	Standard Deviation 0.52
Placebo	Change From Baseline in Body Temperature	Week 12	-0.1 Celsius	Standard Deviation 0.38
GSK2586184 100 mg	Change From Baseline in Body Temperature	Week 12	-0.2 Celsius	Standard Deviation 0.64
GSK2586184 100 mg	Change From Baseline in Body Temperature	Week 8	0.1 Celsius	Standard Deviation 0.51
GSK2586184 100 mg	Change From Baseline in Body Temperature	Week 16	-0.1 Celsius	Standard Deviation 0.66
GSK2586184 100 mg	Change From Baseline in Body Temperature	Week 2	-0.0 Celsius	Standard Deviation 0.38
GSK2586184 100 mg	Change From Baseline in Body Temperature	Week 4	0.1 Celsius	Standard Deviation 0.44
GSK2586184 200 mg	Change From Baseline in Body Temperature	Week 8	-0.2 Celsius	Standard Deviation 0.55
GSK2586184 200 mg	Change From Baseline in Body Temperature	Week 2	-0.1 Celsius	Standard Deviation 0.73
GSK2586184 200 mg	Change From Baseline in Body Temperature	Week 16	0.1 Celsius	Standard Deviation 0.39
GSK2586184 200 mg	Change From Baseline in Body Temperature	Week 4	-0.1 Celsius	Standard Deviation 0.53
GSK2586184 200 mg	Change From Baseline in Body Temperature	Week 12	-0.1 Celsius	Standard Deviation 0.38
GSK2586184 400 mg	Change From Baseline in Body Temperature	Week 12	-0.0 Celsius	Standard Deviation 0.23
GSK2586184 400 mg	Change From Baseline in Body Temperature	Week 2	-0.0 Celsius	Standard Deviation 0.36
GSK2586184 400 mg	Change From Baseline in Body Temperature	Week 16	-0.1 Celsius	Standard Deviation 0.21
GSK2586184 400 mg	Change From Baseline in Body Temperature	Week 8	-0.1 Celsius	Standard Deviation 0.28
GSK2586184 400 mg	Change From Baseline in Body Temperature	Week 4	0.0 Celsius	Standard Deviation 0.28
GSK2586184 400 mg OL	Change From Baseline in Body Temperature	Week 12	0.0 Celsius	Standard Deviation 0.29
GSK2586184 400 mg OL	Change From Baseline in Body Temperature	Week 16	0.4 Celsius	Standard Deviation 0.29
GSK2586184 400 mg OL	Change From Baseline in Body Temperature	Week 8	0.2 Celsius	Standard Deviation 0.51
GSK2586184 400 mg OL	Change From Baseline in Body Temperature	Week 2	0.0 Celsius	Standard Deviation 0.21
GSK2586184 400 mg OL	Change From Baseline in Body Temperature	Week 4	0.3 Celsius	Standard Deviation 0.37
GSK2586184 200 mg OL	Change From Baseline in Body Temperature	Week 8	0.1 Celsius	Standard Deviation 0.21
GSK2586184 200 mg OL	Change From Baseline in Body Temperature	Week 4	0.0 Celsius	Standard Deviation 0
GSK2586184 200 mg OL	Change From Baseline in Body Temperature	Week 2	0.6 Celsius	Standard Deviation 0.49
GSK2586184 200 mg OL	Change From Baseline in Body Temperature	Week 16	-0.0 Celsius	Standard Deviation 0.35
GSK2586184 200 mg OL	Change From Baseline in Body Temperature	Week 12	0.2 Celsius	Standard Deviation 0

Secondary

Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12

Serum Neopterin is a marker of psoriatic disease activity. Blood samples were collected for estimation of serum neoprotein concentration. Baseline was Day 1. The change from Baseline was the difference between post-Baseline and Baseline.

Time frame: Baseline (pre-dose) and Weeks 2, 4, 8 and 12

Population: ITT Population

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12	Week 2	0.19 Nanomol per Liter (nmol/L)	Standard Deviation 1.219
Placebo	Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12	Week 4	0.18 Nanomol per Liter (nmol/L)	Standard Deviation 0.844
Placebo	Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12	Week 8	-0.14 Nanomol per Liter (nmol/L)	Standard Deviation 0.597
Placebo	Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12	Week 12	-0.01 Nanomol per Liter (nmol/L)	Standard Deviation 1.038
GSK2586184 100 mg	Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12	Week 8	-1.13 Nanomol per Liter (nmol/L)	Standard Deviation 2.312
GSK2586184 100 mg	Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12	Week 4	-1.69 Nanomol per Liter (nmol/L)	Standard Deviation 2.933
GSK2586184 100 mg	Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12	Week 2	0.43 Nanomol per Liter (nmol/L)	Standard Deviation 5.394
GSK2586184 100 mg	Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12	Week 12	-1.32 Nanomol per Liter (nmol/L)	Standard Deviation 2.355
GSK2586184 200 mg	Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12	Week 12	-0.79 Nanomol per Liter (nmol/L)	Standard Deviation 1.738
GSK2586184 200 mg	Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12	Week 8	-0.81 Nanomol per Liter (nmol/L)	Standard Deviation 2.294
GSK2586184 200 mg	Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12	Week 4	-1.15 Nanomol per Liter (nmol/L)	Standard Deviation 1.768
GSK2586184 200 mg	Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12	Week 2	2.35 Nanomol per Liter (nmol/L)	Standard Deviation 6.475
GSK2586184 400 mg	Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12	Week 2	-0.42 Nanomol per Liter (nmol/L)	Standard Deviation 1.858
GSK2586184 400 mg	Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12	Week 12	4.37 Nanomol per Liter (nmol/L)	Standard Deviation 13.387
GSK2586184 400 mg	Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12	Week 4	-0.69 Nanomol per Liter (nmol/L)	Standard Deviation 1.195
GSK2586184 400 mg	Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12	Week 8	0.31 Nanomol per Liter (nmol/L)	Standard Deviation 2.998
GSK2586184 400 mg OL	Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12	Week 8	-0.40 Nanomol per Liter (nmol/L)	Standard Deviation 1.52
GSK2586184 400 mg OL	Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12	Week 12	-0.42 Nanomol per Liter (nmol/L)	Standard Deviation 1.182
GSK2586184 400 mg OL	Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12	Week 4	-0.67 Nanomol per Liter (nmol/L)	Standard Deviation 0.378
GSK2586184 400 mg OL	Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12	Week 2	-0.47 Nanomol per Liter (nmol/L)	Standard Deviation 0.918
GSK2586184 200 mg OL	Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12	Week 4	1.80 Nanomol per Liter (nmol/L)	Standard Deviation 2.828
GSK2586184 200 mg OL	Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12	Week 8	0.15 Nanomol per Liter (nmol/L)	Standard Deviation 2.192
GSK2586184 200 mg OL	Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12	Week 12	0.35 Nanomol per Liter (nmol/L)	Standard Deviation 0.212
GSK2586184 200 mg OL	Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12	Week 2	9.95 Nanomol per Liter (nmol/L)	Standard Deviation 13.93

Secondary

Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12

The visual analogue scale (VAS) was used to assess itch. The participants rated the intensity of itch over the past week by marking a line on a 100 millimeter(mm) (0 to 100 mm) long scale. A line placed on the extreme left, that is 0 mm indicated no noticeable itching sensation and extreme right that is 100 mm indicated maximum itching sensation. This scale has no subscales. The participant perception of their symptoms was measured using the VAS itch score. The Baseline value was the value obtained on Day 1. The change from Baseline was the difference between post-Baseline and Baseline.

Time frame: From Baseline (Day 1) until Week 12

Population: ITT Population. Only those participants available at the specified time points were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12	Week 2	-5.67 Scores on a Scale	Standard Deviation 32.129
Placebo	Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12	Week 4	-7.00 Scores on a Scale	Standard Deviation 37.944
Placebo	Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12	Week 8	0.22 Scores on a Scale	Standard Deviation 26.138
Placebo	Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12	Week 12	-1.56 Scores on a Scale	Standard Deviation 34.348
GSK2586184 100 mg	Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12	Week 12	-21.40 Scores on a Scale	Standard Deviation 40.533
GSK2586184 100 mg	Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12	Week 8	-26.27 Scores on a Scale	Standard Deviation 35.707
GSK2586184 100 mg	Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12	Week 2	-14.79 Scores on a Scale	Standard Deviation 31.396
GSK2586184 100 mg	Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12	Week 4	-26.50 Scores on a Scale	Standard Deviation 28.659
GSK2586184 200 mg	Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12	Week 12	-23.92 Scores on a Scale	Standard Deviation 40.586
GSK2586184 200 mg	Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12	Week 4	-22.36 Scores on a Scale	Standard Deviation 27.244
GSK2586184 200 mg	Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12	Week 8	-24.86 Scores on a Scale	Standard Deviation 37.134
GSK2586184 200 mg	Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12	Week 2	-14.87 Scores on a Scale	Standard Deviation 23.67
GSK2586184 400 mg	Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12	Week 2	-24.92 Scores on a Scale	Standard Deviation 24.737
GSK2586184 400 mg	Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12	Week 12	-41.13 Scores on a Scale	Standard Deviation 31.791
GSK2586184 400 mg	Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12	Week 4	-28.08 Scores on a Scale	Standard Deviation 25.678
GSK2586184 400 mg	Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12	Week 8	-36.30 Scores on a Scale	Standard Deviation 29.788
GSK2586184 400 mg OL	Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12	Week 2	-56.33 Scores on a Scale	Standard Deviation 30.329
GSK2586184 400 mg OL	Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12	Week 12	-60.80 Scores on a Scale	Standard Deviation 38.16
GSK2586184 400 mg OL	Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12	Week 4	-47.50 Scores on a Scale	Standard Deviation 39.48
GSK2586184 400 mg OL	Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12	Week 8	-61.50 Scores on a Scale	Standard Deviation 31.729
GSK2586184 200 mg OL	Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12	Week 2	-22.00 Scores on a Scale	Standard Deviation 43.841
GSK2586184 200 mg OL	Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12	Week 8	-32.50 Scores on a Scale	Standard Deviation 65.761
GSK2586184 200 mg OL	Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12	Week 12	-25.00 Scores on a Scale	Standard Deviation 76.368
GSK2586184 200 mg OL	Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12	Week 4	-30.00 Scores on a Scale	Standard Deviation 62.225

Secondary

Change From Baseline of Dermatology Life Quality Index (DLQI) Score at Week 12

The DLQI was used to assess a participant's health-related quality of life. Participants completed the questionnaire to evaluate how their psoriasis affected their life over the week before the assessment took place. Each of the 10 questions was scored out of 0-3 as; 0 = Not at all, 1 = A little, 2 = A lot and 3 = Very much. The total score for the DLQI was calculated by adding up all the individual scores for each question resulting in a minimum of 0 and a maximum of 30. Higher score indicated worsening of participant's quality of life. The Baseline value was the value obtained on Day 1. The change from Baseline was the difference between post-Baseline and Baseline.

Time frame: Baseline and Week 12

Population: ITT Population. Only those participants who had a Week 12 evaluation were analyzed.

Arm	Measure	Value (MEAN)	Dispersion
Placebo	Change From Baseline of Dermatology Life Quality Index (DLQI) Score at Week 12	1.70 Scores on a Scale	Standard Deviation 5.638
GSK2586184 100 mg	Change From Baseline of Dermatology Life Quality Index (DLQI) Score at Week 12	-2.80 Scores on a Scale	Standard Deviation 7.743
GSK2586184 200 mg	Change From Baseline of Dermatology Life Quality Index (DLQI) Score at Week 12	-4.29 Scores on a Scale	Standard Deviation 8.389
GSK2586184 400 mg	Change From Baseline of Dermatology Life Quality Index (DLQI) Score at Week 12	-8.00 Scores on a Scale	Standard Deviation 3.83
GSK2586184 400 mg OL	Change From Baseline of Dermatology Life Quality Index (DLQI) Score at Week 12	-6.75 Scores on a Scale	Standard Deviation 5.123
GSK2586184 200 mg OL	Change From Baseline of Dermatology Life Quality Index (DLQI) Score at Week 12	-8.00 Scores on a Scale	Standard Deviation 11.314

Secondary

Clearance of GSK2586184

Blood samples were taken to measure plasma concentrations of GSK2586184. A two-compartment model with a three-compartment transit model was used to derive PK parameters.

Time frame: Baseline (pre-dose), Day 14 (2 to 3 hour and 3 to 4 hour post-dose), Day 28 (4 to 6 hour and 6 to 8 hour post-dose), Day 56 (at anytime during clinical visit), Day 84 (1 sample to be taken at anytime during clinical visit)

Population: PK Population.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
GSK2586184 100 mg	Clearance of GSK2586184	68.30232 Litre (L)/hr	Geometric Coefficient of Variation 43.9
GSK2586184 200 mg	Clearance of GSK2586184	56.86726 Litre (L)/hr	Geometric Coefficient of Variation 38.7
GSK2586184 400 mg	Clearance of GSK2586184	51.49060 Litre (L)/hr	Geometric Coefficient of Variation 62.4
GSK2586184 400 mg OL	Clearance of GSK2586184	52.89690 Litre (L)/hr	Geometric Coefficient of Variation 79.1
GSK2586184 200 mg OL	Clearance of GSK2586184	62.34017 Litre (L)/hr	Geometric Coefficient of Variation 53.5

Secondary

Itch VAS Scores at Week 2, 4, 8 and 12

The visual analogue scale (VAS) was used to assess itch. The participants rated the intensity of itch over the past week by marking a line on a 100 mm (0 to 100 mm) long scale. A line placed on the extreme left, that is 0 mm indicated no noticeable itching sensation and extreme right that is 100 mm indicated maximum itching sensation. This scale has no subscales. The participant perception of their symptoms was measured using the VAS itch score. Itch VAS scores at Week 2, 4, 8 and 12 are reported.

Time frame: Week 2, 4, 8 and 12

Population: ITT Population. Only those participants available at the specified time points were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Itch VAS Scores at Week 2, 4, 8 and 12	Week 2,n=12,14,15,12,6,2	46.42 Scores on a Scale	Standard Deviation 28.909
Placebo	Itch VAS Scores at Week 2, 4, 8 and 12	Week 4,n=10,12,14,13,6,2	44.40 Scores on a Scale	Standard Deviation 35.485
Placebo	Itch VAS Scores at Week 2, 4, 8 and 12	Week 8,n=9,11,14,11,6,2	57.33 Scores on a Scale	Standard Deviation 29.368
Placebo	Itch VAS Scores at Week 2, 4, 8 and 12	Week 12,n=9,10,13,9,5,2	50.67 Scores on a Scale	Standard Deviation 37.683
GSK2586184 100 mg	Itch VAS Scores at Week 2, 4, 8 and 12	Week 8,n=9,11,14,11,6,2	31.55 Scores on a Scale	Standard Deviation 29.156
GSK2586184 100 mg	Itch VAS Scores at Week 2, 4, 8 and 12	Week 4,n=10,12,14,13,6,2	33.42 Scores on a Scale	Standard Deviation 25.939
GSK2586184 100 mg	Itch VAS Scores at Week 2, 4, 8 and 12	Week 2,n=12,14,15,12,6,2	41.64 Scores on a Scale	Standard Deviation 21.995
GSK2586184 100 mg	Itch VAS Scores at Week 2, 4, 8 and 12	Week 12,n=9,10,13,9,5,2	39.50 Scores on a Scale	Standard Deviation 33.58
GSK2586184 200 mg	Itch VAS Scores at Week 2, 4, 8 and 12	Week 12,n=9,10,13,9,5,2	30.08 Scores on a Scale	Standard Deviation 34.697
GSK2586184 200 mg	Itch VAS Scores at Week 2, 4, 8 and 12	Week 8,n=9,11,14,11,6,2	29.93 Scores on a Scale	Standard Deviation 29.437
GSK2586184 200 mg	Itch VAS Scores at Week 2, 4, 8 and 12	Week 4,n=10,12,14,13,6,2	32.57 Scores on a Scale	Standard Deviation 30.729
GSK2586184 200 mg	Itch VAS Scores at Week 2, 4, 8 and 12	Week 2,n=12,14,15,12,6,2	42.07 Scores on a Scale	Standard Deviation 31.176
GSK2586184 400 mg	Itch VAS Scores at Week 2, 4, 8 and 12	Week 2,n=12,14,15,12,6,2	22.92 Scores on a Scale	Standard Deviation 21.707
GSK2586184 400 mg	Itch VAS Scores at Week 2, 4, 8 and 12	Week 12,n=9,10,13,9,5,2	14.00 Scores on a Scale	Standard Deviation 23.701
GSK2586184 400 mg	Itch VAS Scores at Week 2, 4, 8 and 12	Week 4,n=10,12,14,13,6,2	23.85 Scores on a Scale	Standard Deviation 23.14
GSK2586184 400 mg	Itch VAS Scores at Week 2, 4, 8 and 12	Week 8,n=9,11,14,11,6,2	14.45 Scores on a Scale	Standard Deviation 21.92
GSK2586184 400 mg OL	Itch VAS Scores at Week 2, 4, 8 and 12	Week 8,n=9,11,14,11,6,2	6.67 Scores on a Scale	Standard Deviation 7.763
GSK2586184 400 mg OL	Itch VAS Scores at Week 2, 4, 8 and 12	Week 12,n=9,10,13,9,5,2	5.40 Scores on a Scale	Standard Deviation 6.693
GSK2586184 400 mg OL	Itch VAS Scores at Week 2, 4, 8 and 12	Week 4,n=10,12,14,13,6,2	20.67 Scores on a Scale	Standard Deviation 30.051
GSK2586184 400 mg OL	Itch VAS Scores at Week 2, 4, 8 and 12	Week 2,n=12,14,15,12,6,2	11.83 Scores on a Scale	Standard Deviation 14.73
GSK2586184 200 mg OL	Itch VAS Scores at Week 2, 4, 8 and 12	Week 4,n=10,12,14,13,6,2	34.00 Scores on a Scale	Standard Deviation 41.012
GSK2586184 200 mg OL	Itch VAS Scores at Week 2, 4, 8 and 12	Week 8,n=9,11,14,11,6,2	31.50 Scores on a Scale	Standard Deviation 44.548
GSK2586184 200 mg OL	Itch VAS Scores at Week 2, 4, 8 and 12	Week 12,n=9,10,13,9,5,2	39.00 Scores on a Scale	Standard Deviation 55.154
GSK2586184 200 mg OL	Itch VAS Scores at Week 2, 4, 8 and 12	Week 2,n=12,14,15,12,6,2	42.00 Scores on a Scale	Standard Deviation 22.627

Secondary

Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)

An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, is a congenital anomaly or birth defect. Any SAEs assessed as related to study participation (e.g. study treatment, protocol-mandated procedures, invasive tests, or change in existing therapy) or related to a GSK product was recorded from the time a participant consents to participate in the study up to and including any follow-up contact.

Time frame: From Baseline (Day 1) until the Follow-up visit (Day 112)

Population: ITT Population

Arm	Measure	Group	Value (NUMBER)
Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)	Any AE	13 Participants
Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)	Any SAE	0 Participants
GSK2586184 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)	Any AE	10 Participants
GSK2586184 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)	Any SAE	2 Participants
GSK2586184 200 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)	Any AE	14 Participants
GSK2586184 200 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)	Any SAE	0 Participants
GSK2586184 400 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)	Any AE	10 Participants
GSK2586184 400 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)	Any SAE	1 Participants
GSK2586184 400 mg OL	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)	Any AE	6 Participants
GSK2586184 400 mg OL	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)	Any SAE	1 Participants
GSK2586184 200 mg OL	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)	Any AE	1 Participants
GSK2586184 200 mg OL	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)	Any SAE	0 Participants

Secondary

Number of Participants With the Heart Rate Falling Outside the Clinical Concern Range at Any Time Post-Baseline (BL) During the Study

Vital sign monitoring included heart rate (HR) measurements. HR measurements were taken in supine position after 5 minutes of rest. The number of participants with HR outside the clinical concern range at any time post-BL are presented. HR low was any HR less than 40 beats per minute (bpm) and high was any HR greater than 110 bpm. The BL values were those values obtained at Day 1. Anytime post-BL assessments included any scheduled and unscheduled post-BL assessment.

Time frame: From Baseline (Day 1) until the Follow-up visit (Day 112)

Population: ITT Population. Only those participants available at the specified time points were analyzed.

Arm	Measure	Value (NUMBER)
Placebo	Number of Participants With the Heart Rate Falling Outside the Clinical Concern Range at Any Time Post-Baseline (BL) During the Study	0 Participants
GSK2586184 100 mg	Number of Participants With the Heart Rate Falling Outside the Clinical Concern Range at Any Time Post-Baseline (BL) During the Study	0 Participants
GSK2586184 200 mg	Number of Participants With the Heart Rate Falling Outside the Clinical Concern Range at Any Time Post-Baseline (BL) During the Study	0 Participants
GSK2586184 400 mg	Number of Participants With the Heart Rate Falling Outside the Clinical Concern Range at Any Time Post-Baseline (BL) During the Study	0 Participants
GSK2586184 400 mg OL	Number of Participants With the Heart Rate Falling Outside the Clinical Concern Range at Any Time Post-Baseline (BL) During the Study	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Heart Rate Falling Outside the Clinical Concern Range at Any Time Post-Baseline (BL) During the Study	1 Participants

Secondary

Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study

Safety and tolerability were assessed by measuring the clinical chemistry parameters such as creatinine and cystatin C. BL values were obtained at Day 1. The number of participants with the indicated hematology parameter data outside of the reference range (\> high or \< low) at any time post-BL, including unscheduled or scheduled assessments, are presented.

Time frame: From Baseline (Day 1) until the Follow-up visit (Day 112)

Population: ITT population. Only those participants available at the specified time points were analyzed.

Arm	Measure	Group	Value (NUMBER)
Placebo	Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study	Creatinine, low, n=13,15,16,14,6,2	5 Participants
Placebo	Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study	Creatinine, high, n=13,15,16,14,6,2	1 Participants
Placebo	Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study	Cystatin C, low, n=13,15,16,14,6,2	0 Participants
Placebo	Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study	Cystatin C, high, n=13,15,16,14,6,2	0 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study	Cystatin C, low, n=13,15,16,14,6,2	0 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study	Creatinine, high, n=13,15,16,14,6,2	0 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study	Creatinine, low, n=13,15,16,14,6,2	2 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study	Cystatin C, high, n=13,15,16,14,6,2	0 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study	Cystatin C, high, n=13,15,16,14,6,2	3 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study	Cystatin C, low, n=13,15,16,14,6,2	0 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study	Creatinine, high, n=13,15,16,14,6,2	0 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study	Creatinine, low, n=13,15,16,14,6,2	4 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study	Creatinine, low, n=13,15,16,14,6,2	0 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study	Cystatin C, high, n=13,15,16,14,6,2	0 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study	Creatinine, high, n=13,15,16,14,6,2	1 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study	Cystatin C, low, n=13,15,16,14,6,2	2 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study	Cystatin C, low, n=13,15,16,14,6,2	0 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study	Cystatin C, high, n=13,15,16,14,6,2	0 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study	Creatinine, high, n=13,15,16,14,6,2	0 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study	Creatinine, low, n=13,15,16,14,6,2	1 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study	Creatinine, high, n=13,15,16,14,6,2	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study	Cystatin C, low, n=13,15,16,14,6,2	1 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study	Cystatin C, high, n=13,15,16,14,6,2	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study	Creatinine, low, n=13,15,16,14,6,2	0 Participants

Secondary

Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study

Hematology parameters included: basophils, eosinophils, erythrocyte mean corpuscular hemoglobin (EMCHb) EMCHb concentration (EMCHbC), erythrocyte mean corpuscular volume (EMCV), erythrocyte sedimentation rate (ESR), erythrocytes, hematocrit (fraction 1), hemoglobin, leukocytes, lymphocytes, monocytes, neutrophils, segmented neutrophils, platelets, reticulocytes. BL values were obtained at Day 1. The number of participants with the indicated hematology parameters data outside of the reference range (with high and low) any time post-BL are presented. Anytime post-BL assessments included any scheduled and unscheduled post-BL assessment.

Time frame: From BL (Day 1) until the Follow-up visit (Day 112)

Population: ITT Population. Only those participants available at the specified time points were analyzed. Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.

Arm	Measure	Group	Value (NUMBER)
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCV, high	0 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Eosinophils, low	3 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Reticulocytes, high	2 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Eosinophils, high	0 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCHbC, low	6 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Monocytes, high	1 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Hemoglobin, high	1 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Platelets, low	0 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCV, low	0 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Monocytes, low	2 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Hemoglobin, low	0 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Lymphocytes, high	0 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Neutrophils, Segmented, high	1 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Reticulocytes, low	3 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Neutrophils, Segmented, low	0 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Lymphocytes, low	0 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCHb, high	0 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCHb, low	0 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Hematocrit, high	5 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Erythrocytes, high	1 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Neutrophils, high	1 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Leukocytes, high	3 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Hematocrit, low	0 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Platelets, high	1 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Leukocytes, low	0 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Neutrophils, low	0 Participants
Placebo	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Erythrocytes, low	0 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Platelets, high	1 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Hemoglobin, low	2 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Erythrocytes, high	0 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCV, low	0 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Hematocrit, high	1 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Hematocrit, low	0 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Platelets, low	1 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Reticulocytes, low	5 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Neutrophils, Segmented, high	2 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Neutrophils, Segmented, low	1 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Neutrophils, high	2 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Neutrophils, low	1 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Eosinophils, low	1 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCHb, high	1 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Monocytes, high	0 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Monocytes, low	1 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Eosinophils, high	0 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Reticulocytes, high	4 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Lymphocytes, high	0 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCHbC, low	5 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Lymphocytes, low	0 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Leukocytes, high	2 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCHb, low	1 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCV, high	1 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Erythrocytes, low	1 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Leukocytes, low	2 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Hemoglobin, high	1 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCHbC, low	7 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCHb, high	2 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCV, low	1 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Hematocrit, low	0 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Neutrophils, Segmented, high	3 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Eosinophils, low	0 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Eosinophils, high	0 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCHb, low	1 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCV, high	3 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	ESR, high	1 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Erythrocytes, low	2 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Erythrocytes, high	0 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Hematocrit, high	4 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Hemoglobin, low	2 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Hemoglobin, high	0 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Leukocytes, low	3 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Leukocytes, high	4 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Lymphocytes, low	4 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Lymphocytes, high	2 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Monocytes, low	2 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Monocytes, high	1 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Neutrophils, low	1 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Neutrophils, high	3 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Neutrophils, Segmented, low	1 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Platelets, low	0 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Platelets, high	1 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Reticulocytes, low	5 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Reticulocytes, high	3 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Neutrophils, Segmented, high	2 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Eosinophils, high	2 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Neutrophils, Segmented, low	1 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCV, high	2 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Monocytes, low	3 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Reticulocytes, high	1 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCHb, low	0 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Hematocrit, high	0 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Eosinophils, low	3 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Reticulocytes, low	4 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Monocytes, high	0 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Leukocytes, high	1 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Neutrophils, high	2 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCV, low	0 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Neutrophils, low	1 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Platelets, high	0 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Erythrocytes, high	0 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Erythrocytes, low	1 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCHbC, low	5 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCHb, high	2 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Lymphocytes, low	2 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Leukocytes, low	0 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Hematocrit, low	2 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Platelets, low	1 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Hemoglobin, high	1 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	ESR, high	0 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Lymphocytes, high	0 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Hemoglobin, low	0 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCV, low	0 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Hemoglobin, high	1 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	ESR, high	0 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCV, high	3 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Platelets, high	0 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Leukocytes, low	0 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Leukocytes, high	1 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCHbC, low	3 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Lymphocytes, low	0 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Eosinophils, high	0 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Lymphocytes, high	0 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Reticulocytes, high	3 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Monocytes, low	2 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Eosinophils, low	2 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Monocytes, high	0 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Neutrophils, low	0 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Reticulocytes, low	0 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCHb, low	0 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Neutrophils, high	2 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Neutrophils, Segmented, low	0 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Hemoglobin, low	0 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Neutrophils, Segmented, high	2 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Platelets, low	0 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Hematocrit, low	0 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Erythrocytes, high	0 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCHb, high	3 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Hematocrit, high	2 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Erythrocytes, low	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Neutrophils, Segmented, low	1 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Neutrophils, high	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Hemoglobin, low	1 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Lymphocytes, high	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Hematocrit, high	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCHb, low	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCV, high	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Reticulocytes, high	1 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Eosinophils, high	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Erythrocytes, low	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Platelets, low	1 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCHb, high	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Erythrocytes, high	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Lymphocytes, low	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Hemoglobin, high	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Reticulocytes, low	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	ESR, high	1 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Hematocrit, low	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Neutrophils, low	1 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCV, low	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	EMCHbC, low	2 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Leukocytes, high	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Monocytes, high	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Leukocytes, low	1 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Neutrophils, Segmented, high	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Monocytes, low	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Eosinophils, low	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study	Platelets, high	0 Participants

Secondary

Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings

ECG measurements were obtained using single 12-lead ECGs with the participant in a supine position after resting in this position for at least 10 minutes. The Baseline values were those values obtained Pre-dose on Day 1. The change from Baseline was the difference between post-Baseline and Baseline. The QT intervals (milliseconds \[msec\]) corrected for heart rate using Bazett's formula (QTcB) and Fridericia's formula (QTcF) are reported.

Time frame: From Baseline (Day 1) until the Follow-up visit (Day 112)

Population: ITT Population.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Placebo	Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings	QTcB, <30 msec	13 Participants
Placebo	Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings	QTcB, >=30 to <60 msec	0 Participants
Placebo	Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings	QTcF, <30 msec	13 Participants
Placebo	Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings	QTcF, >=30 to <60 msec	0 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings	QTcF, <30 msec	15 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings	QTcB, >=30 to <60 msec	1 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings	QTcB, <30 msec	14 Participants
GSK2586184 100 mg	Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings	QTcF, >=30 to <60 msec	0 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings	QTcF, >=30 to <60 msec	0 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings	QTcF, <30 msec	16 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings	QTcB, >=30 to <60 msec	0 Participants
GSK2586184 200 mg	Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings	QTcB, <30 msec	16 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings	QTcB, <30 msec	12 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings	QTcF, >=30 to <60 msec	2 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings	QTcB, >=30 to <60 msec	2 Participants
GSK2586184 400 mg	Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings	QTcF, <30 msec	12 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings	QTcF, <30 msec	6 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings	QTcF, >=30 to <60 msec	0 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings	QTcB, >=30 to <60 msec	0 Participants
GSK2586184 400 mg OL	Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings	QTcB, <30 msec	6 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings	QTcB, >=30 to <60 msec	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings	QTcF, <30 msec	2 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings	QTcB, <30 msec	2 Participants
GSK2586184 200 mg OL	Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings	QTcF, >=30 to <60 msec	0 Participants

Secondary

Number of Participants With the Systolic (S) and Diastolic (D) Blood Pressure (BP) Falling Outside the Clinical Concern Range at Any Time Post-baseline During the Study

Vital sign monitoring included systolic and diastolic BP measurements. BP measurements were taken in the supine position after 5 minutes of rest. The number of participants with the SBP or DBP outside the clinical concern range at any time post-BL are presented. SBP low was measured as less than 85 millimeters of mercury (mmHg)and high was measured as greater than 160 mmHg. DBP low was measured as less than 45 mmHg and high was measured as greater than 100 mmHg. The BL values were those values obtained at Day 1. Anytime post-BL assessments included any scheduled and unscheduled post-BL assessment.

Time frame: From Baseline (Day 1) until the follow-up visit (Day 112)

Population: ITT Population. Only those participants available at the specified time points were analyzed.

Arm	Measure	Group	Value (NUMBER)
Placebo	Number of Participants With the Systolic (S) and Diastolic (D) Blood Pressure (BP) Falling Outside the Clinical Concern Range at Any Time Post-baseline During the Study	DBP, low	0 Participants
Placebo	Number of Participants With the Systolic (S) and Diastolic (D) Blood Pressure (BP) Falling Outside the Clinical Concern Range at Any Time Post-baseline During the Study	SBP, high	1 Participants
Placebo	Number of Participants With the Systolic (S) and Diastolic (D) Blood Pressure (BP) Falling Outside the Clinical Concern Range at Any Time Post-baseline During the Study	DBP, high	3 Participants
GSK2586184 100 mg	Number of Participants With the Systolic (S) and Diastolic (D) Blood Pressure (BP) Falling Outside the Clinical Concern Range at Any Time Post-baseline During the Study	DBP, low	0 Participants
GSK2586184 100 mg	Number of Participants With the Systolic (S) and Diastolic (D) Blood Pressure (BP) Falling Outside the Clinical Concern Range at Any Time Post-baseline During the Study	SBP, high	0 Participants
GSK2586184 100 mg	Number of Participants With the Systolic (S) and Diastolic (D) Blood Pressure (BP) Falling Outside the Clinical Concern Range at Any Time Post-baseline During the Study	DBP, high	0 Participants
GSK2586184 200 mg	Number of Participants With the Systolic (S) and Diastolic (D) Blood Pressure (BP) Falling Outside the Clinical Concern Range at Any Time Post-baseline During the Study	DBP, low	0 Participants
GSK2586184 200 mg	Number of Participants With the Systolic (S) and Diastolic (D) Blood Pressure (BP) Falling Outside the Clinical Concern Range at Any Time Post-baseline During the Study	SBP, high	0 Participants
GSK2586184 200 mg	Number of Participants With the Systolic (S) and Diastolic (D) Blood Pressure (BP) Falling Outside the Clinical Concern Range at Any Time Post-baseline During the Study	DBP, high	0 Participants
GSK2586184 400 mg	Number of Participants With the Systolic (S) and Diastolic (D) Blood Pressure (BP) Falling Outside the Clinical Concern Range at Any Time Post-baseline During the Study	DBP, low	0 Participants
GSK2586184 400 mg	Number of Participants With the Systolic (S) and Diastolic (D) Blood Pressure (BP) Falling Outside the Clinical Concern Range at Any Time Post-baseline During the Study	SBP, high	1 Participants
GSK2586184 400 mg	Number of Participants With the Systolic (S) and Diastolic (D) Blood Pressure (BP) Falling Outside the Clinical Concern Range at Any Time Post-baseline During the Study	DBP, high	2 Participants
GSK2586184 400 mg OL	Number of Participants With the Systolic (S) and Diastolic (D) Blood Pressure (BP) Falling Outside the Clinical Concern Range at Any Time Post-baseline During the Study	DBP, low	0 Participants
GSK2586184 400 mg OL	Number of Participants With the Systolic (S) and Diastolic (D) Blood Pressure (BP) Falling Outside the Clinical Concern Range at Any Time Post-baseline During the Study	SBP, high	1 Participants
GSK2586184 400 mg OL	Number of Participants With the Systolic (S) and Diastolic (D) Blood Pressure (BP) Falling Outside the Clinical Concern Range at Any Time Post-baseline During the Study	DBP, high	1 Participants
GSK2586184 200 mg OL	Number of Participants With the Systolic (S) and Diastolic (D) Blood Pressure (BP) Falling Outside the Clinical Concern Range at Any Time Post-baseline During the Study	SBP, high	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Systolic (S) and Diastolic (D) Blood Pressure (BP) Falling Outside the Clinical Concern Range at Any Time Post-baseline During the Study	DBP, high	0 Participants
GSK2586184 200 mg OL	Number of Participants With the Systolic (S) and Diastolic (D) Blood Pressure (BP) Falling Outside the Clinical Concern Range at Any Time Post-baseline During the Study	DBP, low	0 Participants

Secondary

PASI Score at Week 2, 4, 8 and 12

Time frame: Week 2, 4, 8 and 12

Population: ITT Population. Only those participants available at the specified time points were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	PASI Score at Week 2, 4, 8 and 12	Week 2	16.33 Scores on a Scale	Standard Deviation 4.896
Placebo	PASI Score at Week 2, 4, 8 and 12	Week 4	15.12 Scores on a Scale	Standard Deviation 4.683
Placebo	PASI Score at Week 2, 4, 8 and 12	Week 8	14.64 Scores on a Scale	Standard Deviation 4.289
Placebo	PASI Score at Week 2, 4, 8 and 12	Week 12	12.92 Scores on a Scale	Standard Deviation 3.384
GSK2586184 100 mg	PASI Score at Week 2, 4, 8 and 12	Week 8	12.56 Scores on a Scale	Standard Deviation 5.442
GSK2586184 100 mg	PASI Score at Week 2, 4, 8 and 12	Week 4	13.94 Scores on a Scale	Standard Deviation 6.616
GSK2586184 100 mg	PASI Score at Week 2, 4, 8 and 12	Week 2	16.56 Scores on a Scale	Standard Deviation 5.708
GSK2586184 100 mg	PASI Score at Week 2, 4, 8 and 12	Week 12	10.52 Scores on a Scale	Standard Deviation 4.932
GSK2586184 200 mg	PASI Score at Week 2, 4, 8 and 12	Week 12	9.67 Scores on a Scale	Standard Deviation 7.799
GSK2586184 200 mg	PASI Score at Week 2, 4, 8 and 12	Week 8	11.03 Scores on a Scale	Standard Deviation 8.322
GSK2586184 200 mg	PASI Score at Week 2, 4, 8 and 12	Week 4	12.59 Scores on a Scale	Standard Deviation 5.524
GSK2586184 200 mg	PASI Score at Week 2, 4, 8 and 12	Week 2	18.92 Scores on a Scale	Standard Deviation 9.969
GSK2586184 400 mg	PASI Score at Week 2, 4, 8 and 12	Week 2	13.39 Scores on a Scale	Standard Deviation 5.594
GSK2586184 400 mg	PASI Score at Week 2, 4, 8 and 12	Week 12	4.03 Scores on a Scale	Standard Deviation 4.666
GSK2586184 400 mg	PASI Score at Week 2, 4, 8 and 12	Week 4	9.58 Scores on a Scale	Standard Deviation 7.91
GSK2586184 400 mg	PASI Score at Week 2, 4, 8 and 12	Week 8	7.30 Scores on a Scale	Standard Deviation 9.11
GSK2586184 400 mg OL	PASI Score at Week 2, 4, 8 and 12	Week 8	11.15 Scores on a Scale	Standard Deviation 9.573
GSK2586184 400 mg OL	PASI Score at Week 2, 4, 8 and 12	Week 12	9.63 Scores on a Scale	Standard Deviation 10.688
GSK2586184 400 mg OL	PASI Score at Week 2, 4, 8 and 12	Week 4	9.90 Scores on a Scale	Standard Deviation 6.271
GSK2586184 400 mg OL	PASI Score at Week 2, 4, 8 and 12	Week 2	13.75 Scores on a Scale	Standard Deviation 4.807
GSK2586184 200 mg OL	PASI Score at Week 2, 4, 8 and 12	Week 4	6.75 Scores on a Scale	Standard Deviation 1.485
GSK2586184 200 mg OL	PASI Score at Week 2, 4, 8 and 12	Week 8	3.45 Scores on a Scale	Standard Deviation 2.899
GSK2586184 200 mg OL	PASI Score at Week 2, 4, 8 and 12	Week 12	2.50 Scores on a Scale	Standard Deviation 3.536
GSK2586184 200 mg OL	PASI Score at Week 2, 4, 8 and 12	Week 2	11.20 Scores on a Scale	Standard Deviation 0.283

Secondary

Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12

The severity of psoriatic lesions over the whole body were assessed by the investigator using the PGA scoring system. A 0 to 6 point rating scale was used, as follows: 0 = Clear (no signs of psoriasis), 1 = Almost clear (slight elevation, scale and/or erythema), 2 = Mild (mild plaque elevation, scale and/or erythema), 3 = Mild to moderate (mild plaque elevation with moderate erythema and/or scale), 4 = Moderate (moderate plaque elevation, scale and/or erythema), 5 = Moderate to severe (marked plaque elevation, scale and/or erythema), 6 = Severe (very marked plaque elevation, scale and/or erythema). Higher scores indicated worse psoriasis. The Baseline value was the value obtained on Day 1. The scores were reported with the last observation carried forward (LOCF) analysis.

Time frame: Weeks 2, 4, 8 and 12

Population: ITT Population. Only those participants available at the specified time points were analyzed.

Arm	Measure	Group	Value (NUMBER)
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, mild	0 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, almost clear	0 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, moderate to severe	10 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, Clear	0 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, moderate,	44 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, Clear	0 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, mild to moderate	23 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, moderate	50 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, moderate	50 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, mild to moderate	22 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, Clear	0 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, mild	0 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, moderate	46 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, mild to moderate	25 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, mild to moderate	30 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, almost clear	0 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, almost clear	0 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, mild	0 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, moderate to severe	31 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, mild	10 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, severe	0 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, Clear	0 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, almost clear	0 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, severe	0 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, severe	0 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, moderate to severe	33 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, Severe	0 Percentage of Participants
Placebo	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, moderate to severe	25 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, moderate to severe	14 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, moderate	29 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, Clear	0 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, Severe	0 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, mild to moderate	36 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, almost clear	0 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, mild	14 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, almost clear	10 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, Clear	0 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, Clear	0 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, severe	9 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, almost clear	0 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, moderate to severe	10 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, moderate to severe	9 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, mild	0 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, moderate	30 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, moderate,	36 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, mild to moderate	27 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, mild to moderate	14 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, mild to moderate	50 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, mild	9 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, moderate	64 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, almost clear	9 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, Clear	0 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, moderate to severe	14 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, mild	0 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, severe	7 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, severe	7 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, moderate,	33 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, moderate to severe	21 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, Severe	0 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, Clear	0 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, almost clear	6 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, mild	0 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, mild to moderate	19 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, moderate	44 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, moderate to severe	13 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, severe	19 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, Clear	0 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, almost clear	7 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, mild	0 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, mild to moderate	29 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, moderate	43 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, moderate to severe	14 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, severe	7 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, Clear	0 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, almost clear	7 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, mild	20 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, mild to moderate	20 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, moderate to severe	13 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, severe	7 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, Clear	7 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, almost clear	21 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, mild	0 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, mild to moderate	29 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, moderate	21 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, moderate	0 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, Clear	0 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, Clear	30 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, almost clear	20 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, moderate	36 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, almost clear	0 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, mild	23 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, almost clear	31 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, Severe	10 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, mild to moderate	54 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, severe	7 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, Clear	0 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, moderate	8 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, mild	23 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, mild	20 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, mild to moderate	43 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, severe	0 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, moderate to severe	0 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, mild to moderate	23 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, mild	0 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, Clear	0 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, moderate,	8 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, moderate to severe	14 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, moderate to severe	8 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, moderate to severe	15 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, almost clear	0 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, mild to moderate	20 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, severe	8 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, mild to moderate	33 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, Clear	0 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, moderate to severe	17 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, mild to moderate	33 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, severe	0 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, Clear	0 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, Clear	0 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, moderate to severe	17 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, Severe	0 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, moderate	50 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, mild	50 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, almost clear	17 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, moderate to severe	33 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, almost clear	0 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, moderate,	0 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, severe	17 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, moderate	17 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, mild	33 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, mild	17 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, almost clear	0 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, Clear	0 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, almost clear	0 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, mild to moderate	17 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, mild to moderate	33 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, severe	0 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, mild	0 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, moderate to severe	0 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, moderate	17 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, moderate to severe	0 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, moderate	100 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, moderate	0 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, moderate to severe	0 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, moderate to severe	50 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, severe	0 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, moderate	50 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, Clear	0 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, mild	0 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, almost clear	50 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, mild to moderate	0 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, mild	0 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, mild	0 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, mild to moderate	50 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, moderate,	0 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, almost clear	0 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, moderate to severe	0 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, Clear	0 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 8, severe	0 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, Clear	50 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, Severe	0 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, mild to moderate	50 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, almost clear	0 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 12, almost clear	0 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, mild	0 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, Clear	0 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 4, mild to moderate	0 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12	Week 2, severe	0 Percentage of Participants

Secondary

Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12

Time frame: From Baseline (Day 1) until Week 12

Population: ITT Population.

Arm	Measure	Group	Value (NUMBER)
Placebo	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 50, Week 12	0 Percentage of Participants
Placebo	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 90, Week 12	0 Percentage of Participants
Placebo	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 90, Week 8	0 Percentage of Participants
Placebo	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 75, Week 12	0 Percentage of Participants
Placebo	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 50, Week 8	0 Percentage of Participants
Placebo	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 75, Week 4	0 Percentage of Participants
Placebo	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 50, Week 4	0 Percentage of Participants
Placebo	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 75, Week 8	0 Percentage of Participants
Placebo	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 50, Week 2	0 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 75, Week 4	7 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 90, Week 8	7 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 75, Week 12	13 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 75, Week 8	7 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 50, Week 4	13 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 50, Week 2	7 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 50, Week 8	20 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 90, Week 12	0 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 50, Week 12	27 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 50, Week 2	6 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 50, Week 4	25 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 75, Week 4	6 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 50, Week 12	31 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 90, Week 12	25 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 75, Week 12	25 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 90, Week 8	6 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 75, Week 8	25 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 50, Week 8	31 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 50, Week 12	64 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 90, Week 12	36 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 75, Week 12	57 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 50, Week 4	57 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 50, Week 8	71 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 90, Week 8	14 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 50, Week 2	7 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 75, Week 4	21 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 75, Week 8	50 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 75, Week 8	17 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 50, Week 2	17 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 75, Week 4	0 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 50, Week 12	50 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 75, Week 12	50 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 50, Week 8	50 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 50, Week 4	50 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 90, Week 12	17 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 90, Week 8	0 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 90, Week 12	50 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 50, Week 2	0 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 50, Week 4	100 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 50, Week 8	100 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 50, Week 12	100 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 75, Week 4	0 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 75, Week 8	50 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 75, Week 12	50 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12	PASI 90, Week 8	0 Percentage of Participants

Secondary

Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12

Time frame: Weeks 2, 4, 8 and 12

Population: ITT Population

Arm	Measure	Group	Value (NUMBER)
Placebo	Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12	Week 2	0 Percentage of Participants
Placebo	Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12	Week 4	0 Percentage of Participants
Placebo	Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12	Week 8	0 Percentage of Participants
Placebo	Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12	Week 12	0 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12	Week 8	7 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12	Week 4	0 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12	Week 2	0 Percentage of Participants
GSK2586184 100 mg	Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12	Week 12	7 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12	Week 12	25 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12	Week 8	6 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12	Week 4	6 Percentage of Participants
GSK2586184 200 mg	Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12	Week 2	6 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12	Week 2	0 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12	Week 12	43 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12	Week 4	0 Percentage of Participants
GSK2586184 400 mg	Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12	Week 8	29 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12	Week 8	0 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12	Week 12	17 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12	Week 4	0 Percentage of Participants
GSK2586184 400 mg OL	Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12	Week 2	0 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12	Week 4	0 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12	Week 8	50 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12	Week 12	50 Percentage of Participants
GSK2586184 200 mg OL	Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12	Week 2	0 Percentage of Participants

Secondary

Population Pharmacokinetic (PK) Derived Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Time of the Last Measureable Concentration (AUC(0-tau) of GSK2586184

Blood samples were taken to measure plasma concentrations of GSK2586184. A two-compartment model with a three-compartment transit model was used to derive PK parameters.

Population: PK population. The PK Population comprised of all participants who were randomized and received at least one dose of study medication.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
GSK2586184 100 mg	Population Pharmacokinetic (PK) Derived Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Time of the Last Measureable Concentration (AUC(0-tau) of GSK2586184	1464.07903 Nanogram/milliLitrehour (ng/mLhr)	Geometric Coefficient of Variation 43.9
GSK2586184 200 mg	Population Pharmacokinetic (PK) Derived Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Time of the Last Measureable Concentration (AUC(0-tau) of GSK2586184	3516.96224 Nanogram/milliLitrehour (ng/mLhr)	Geometric Coefficient of Variation 38.7
GSK2586184 400 mg	Population Pharmacokinetic (PK) Derived Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Time of the Last Measureable Concentration (AUC(0-tau) of GSK2586184	7768.40786 Nanogram/milliLitrehour (ng/mLhr)	Geometric Coefficient of Variation 62.4
GSK2586184 400 mg OL	Population Pharmacokinetic (PK) Derived Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Time of the Last Measureable Concentration (AUC(0-tau) of GSK2586184	7561.87974 Nanogram/milliLitrehour (ng/mLhr)	Geometric Coefficient of Variation 79.1
GSK2586184 200 mg OL	Population Pharmacokinetic (PK) Derived Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Time of the Last Measureable Concentration (AUC(0-tau) of GSK2586184	3208.20452 Nanogram/milliLitrehour (ng/mLhr)	Geometric Coefficient of Variation 53.5

Secondary

Steady State Volume of Distribution (Vss) of GSK2586184

Blood samples were taken to measure plasma concentrations of GSK2586184. A two-compartment model with a three-compartment transit model was used to derive PK parameters.

Population: PK Population

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
GSK2586184 100 mg	Steady State Volume of Distribution (Vss) of GSK2586184	244.10260 L	Geometric Coefficient of Variation 62.3
GSK2586184 200 mg	Steady State Volume of Distribution (Vss) of GSK2586184	193.75344 L	Geometric Coefficient of Variation 47.1
GSK2586184 400 mg	Steady State Volume of Distribution (Vss) of GSK2586184	186.78323 L	Geometric Coefficient of Variation 64.4
GSK2586184 400 mg OL	Steady State Volume of Distribution (Vss) of GSK2586184	199.73746 L	Geometric Coefficient of Variation 85.4
GSK2586184 200 mg OL	Steady State Volume of Distribution (Vss) of GSK2586184	216.00359 L	Geometric Coefficient of Variation 66.5

Secondary

Time to PASI 75

PASI 75 was \>= 75% improvement from Baseline in PASI score. Psoriatic lesions were assessed by the investigator using a PASI score. PASI score was determined by evaluation of BSA covered by plaque psoriasis in 4 areas (head/neck, arms, trunk and legs with area score of 0.1, 0.2, 0.3 and 0.4 respectively). This test included combination of both degree of involvement (assessed as per the % of affected body area using a 7-point scale such that 0=0% involvement, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%) and severity (evaluated individually using a 5-point scale that ranged as 0=No evidence of sign, 1=slight evidence, 2=moderate evidence, 3=marked evidence and 4=very marked, most severe evidence of sign) of erythema, induration and desquamation in each of the same 4 areas. PASI score ranges from 0(no psoriasis) to 72(worse psoriasis). Final PASI=(sum of severity score for each area)x(% body affected score x area score). Baseline was Day 1.

Time frame: From Baseline (Day 1) until Week 12

Population: ITT Population. Only participants achieving PASI 75 were analyzed.

Arm	Measure	Value (MEDIAN)
GSK2586184 100 mg	Time to PASI 75	59 Days
GSK2586184 200 mg	Time to PASI 75	55.5 Days
GSK2586184 400 mg	Time to PASI 75	57 Days
GSK2586184 400 mg OL	Time to PASI 75	84 Days
GSK2586184 200 mg OL	Time to PASI 75	57 Days

Secondary

Time to PGA Score of 'Clear' (0) or 'Almost Clear' (1)

The severity of psoriatic lesions over the whole body were assessed by the investigator using the PGA scoring system. A 0 to 6 point rating scale was used, as follows: 0 = Clear (no signs of psoriasis), 1 = Almost clear (slight elevation, scale and/or erythema), 2 = Mild (mild plaque elevation, scale and/or erythema), 3 = Mild to moderate (mild plaque elevation with moderate erythema and/or scale)4 = Moderate (moderate plaque elevation, scale and/or erythema), 5 = Moderate to severe (marked plaque elevation, scale and/or erythema), 6 = Severe (very marked plaque elevation, scale and/or erythema). The Baseline value was the value obtained on Day 1. The scores were reported with the last observation carried forward (LOCF) analysis.

Time frame: From Baseline (Day 1) until Week 12

Population: ITT Population. Only participants achieving a PGA score of 'Clear' or 'Almost Clear' were analyzed.

Arm	Measure	Value (MEDIAN)
GSK2586184 100 mg	Time to PGA Score of 'Clear' (0) or 'Almost Clear' (1)	55 Days
GSK2586184 200 mg	Time to PGA Score of 'Clear' (0) or 'Almost Clear' (1)	84.5 Days
GSK2586184 400 mg	Time to PGA Score of 'Clear' (0) or 'Almost Clear' (1)	57 Days
GSK2586184 400 mg OL	Time to PGA Score of 'Clear' (0) or 'Almost Clear' (1)	84 Days
GSK2586184 200 mg OL	Time to PGA Score of 'Clear' (0) or 'Almost Clear' (1)	57 Days

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026

A Dose Ranging Study to Evaluate the Safety and Efficacy of GSK2586184 in Patients With Chronic Plaque Psoriasis

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Percentage of Participants Who Had Achieved >=75% Improvement From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 12 (PASI 75)

Percentage of Participants Who Had Achieved >=75% Improvement From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 12 (PASI 75)

Change From Baseline (BL) in the PASI Score at Week 2, 4, 8 and 12

Change From Baseline in Body Temperature

Change From Baseline in Serum Neopterin Concentrations at Weeks 2, 4, 8 and 12

Change From Baseline in the Itch Visual Analogue Scale (VAS) Score at Week 2, 4, 8 and 12

Change From Baseline of Dermatology Life Quality Index (DLQI) Score at Week 12

Clearance of GSK2586184

Itch VAS Scores at Week 2, 4, 8 and 12

Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)

Number of Participants With the Heart Rate Falling Outside the Clinical Concern Range at Any Time Post-Baseline (BL) During the Study

Number of Participants With the Indicated Clinical Chemistry Parameters Falling Outside the Reference Range at Any Time Post-Baseline (BL) During the Study

Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline (BL) During Study

Number of Participants With the Indicated Maximum Change From Baseline in the Electrocardiogram (ECG) Findings

Number of Participants With the Systolic (S) and Diastolic (D) Blood Pressure (BP) Falling Outside the Clinical Concern Range at Any Time Post-baseline During the Study

PASI Score at Week 2, 4, 8 and 12

Percentage of Participants in Each PGA Score Category at Weeks 2, 4, 8 and 12

Percentage of Participants Who Had a PASI Score With 50%, 75% and 90% Improvement From Baseline Until Week 12

Percentage of Participants Who Had a Physician Global Assessment (PGA) Score of 'Clear' (0) or 'Almost Clear' (1) at Weeks 2, 4, 8 and 12

Population Pharmacokinetic (PK) Derived Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Time of the Last Measureable Concentration (AUC(0-tau) of GSK2586184

Steady State Volume of Distribution (Vss) of GSK2586184

Time to PASI 75

Time to PGA Score of 'Clear' (0) or 'Almost Clear' (1)